Compare RWT & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RWT | CSTL |
|---|---|---|
| Founded | 1994 | 2007 |
| Country | United States | United States |
| Employees | 351 | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.5M | 806.3M |
| IPO Year | N/A | 2019 |
| Metric | RWT | CSTL |
|---|---|---|
| Price | $6.07 | $24.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $6.91 | ★ $47.17 |
| AVG Volume (30 Days) | ★ 1.4M | 255.8K |
| Earning Date | 04-27-2026 | 05-04-2026 |
| Dividend Yield | ★ 11.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | $26.59 | $2.42 |
| Revenue Next Year | $22.21 | $12.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $5.00 | $14.59 |
| 52 Week High | $6.97 | $44.28 |
| Indicator | RWT | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 62.09 | 42.64 |
| Support Level | $5.91 | $21.77 |
| Resistance Level | $6.20 | $26.44 |
| Average True Range (ATR) | 0.14 | 1.13 |
| MACD | 0.07 | 0.25 |
| Stochastic Oscillator | 95.38 | 56.85 |
Redwood Trust Inc is a specialty finance company focused on several distinct areas of housing credit. The company delivers customized housing credit investments to a diverse mix of investors through securitization platforms, whole-loan distribution activities, and its publicly traded securities. The company has four reportable segments: Sequoia Mortgage Banking, CoreVest Mortgage Banking, Redwood Investments, and Legacy Investments. Maximum revenue is generated from the Sequoia Mortgage Banking segment, comprising a mortgage loan conduit that acquires residential consumer loans from third-party originators for subsequent sale to whole loan buyers, securitization through its SEMT private-label securitization program, or transfer into its Redwood Investments portfolio.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.